PASG: 繼續泄，還是真反轉了？

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

cash 情況：366M，可以跑5個季度（？）

產品：無

上市：今年大崩潰前。

現在情況：六月底到頂後連續下降（表麵沒有原因），至少三天沒有往下走了。主觀判斷：可能小反彈。（笑翻天）

昨天沒有管住手，買了幾股。（下定決心再也不買了。Really？）

 

PS：“G & G 媽” 網友昨天也說了這個股票。